When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair ... with the scientific team ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Management also lowered the midpoint ... The Motley Fool Stock Advisor analyst team just identified what they believe are the ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.

The top 10 get 32% of the ETF’s total assets. Under the same management team as SCHX and SCHG, SCHK has a 0.05% expense ratio and a trailing-12-month yield of 1.2%. The fund has a five-year annualized ...

How the Development Bank of Wales supports tech-driven companies, ranging from start-ups to established businesses ...

In September, the company officially relocated its headquarters from a 114,000-square-foot space in New York City to a ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...